Digital pathology & AI
Scanning microscope slides and letting software measure things a pathologist cannot see, including predictions of who will benefit from a treatment.
Whole-slide imaging is now routine in many centres. FDA-cleared tools: Paige Prostate (detection), ArteraAI Prostate (2025, first prognostic and predictive AI) and ArteraAI Breast (May 2026, risk stratification in early HR+/HER2- breast cancer). Foundation models (Virchow, UNI, CONCH, Prov-GigaPath) predict molecular status (MSI, HRD, HER2) from H&E alone.
How it works
Gigapixel whole-slide images; tile-level self-supervised encoders aggregated to slide-level predictions.
- Cheap biomarker from routine slides
- Consistent scoring (Ki-67, TILs, HER2)
- Scanner and stain domain shift
- Explainability
- Regulatory pathways for updates
An FDA-cleared AI test (May 2026) that reads breast cancer slides to estimate recurrence risk in early hormone-positive disease.
The first AI tool cleared by the FDA to predict both prognosis and treatment benefit from a routine biopsy slide, in prostate cancer.
Latest papers
topQuery for this technology: (TITLE:"digital pathology" OR ABSTRACT:"digital pathology" OR TITLE:"computational pathology" OR ABSTRACT:"computational pathology" OR TITLE:"whole slide image" OR ABSTRACT:"whole slide image") AND (deep learning OR artificial intelligence). Results are unfiltered search hits about Digital pathology & AI, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyHistopathology & immunohistochemistry
Shares TIL-based omission of chemotherapy in stage I TNBC, Histology (histological subtype), A standard evaluation pathway for AI-assisted pathology, from reader study to deployment, Digitise the nation's pathology slides and link them to outcomes.
- TechnologyAI in radiology
Shares A dedicated fund for randomised trials of cancer AI with patient outcomes, Continuous prospective validation for every oncology AI tool after deployment, Oncology workforce, Federated training of pathology and radiology models across hospitals.
- Company10x Genomics
Shares Map which tumour clones sit next to which immune cells before choosing therapy, Standards for spatial and multiplex tissue biomarkers before they reach the clinic, Spatial-omics-guided treatment selection, Turn the map of immune cells inside a tumour into a standardised test.
- TermHot vs cold tumours
Shares Map which tumour clones sit next to which immune cells before choosing therapy, Standards for spatial and multiplex tissue biomarkers before they reach the clinic, Clear the suppressive neutrophils out of pancreatic tumours first, Spatial-omics-guided treatment selection.
- TechnologySingle-cell & spatial profiling
Shares Map which tumour clones sit next to which immune cells before choosing therapy, Standards for spatial and multiplex tissue biomarkers before they reach the clinic, Clear the suppressive neutrophils out of pancreatic tumours first, Spatial-omics-guided treatment selection.
- TechnologyTelemedicine, teleoncology, and telepathology
Shares Proscia, Butaro Cancer Center of Excellence, Whole-slide scanners and image management.
- CompanyTempus AI
Shares A pre-competitive consortium to train a shared multimodal cancer foundation model, Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, AI that is built but not validated or deployed.
- TechnologyMammography & tomosynthesis
Shares A dedicated fund for randomised trials of cancer AI with patient outcomes, Lunit, AI in the oncology clinic: from narrow cleared tools to multimodal decision support, AI that is built but not validated or deployed.